UPDATE: JPMorgan Starts Monte Rosa Therapeutics (GLUE) at Overweight

JPMorgan analyst Eric Joseph initiates coverage on Monte Rosa Therapeutics (NASDAQ: GLUE) with a Overweight rating and a price target of $38.00.

The analyst comments "We rate GLUE shares Overweight based on what we view as a differentiated drug development platform within the oral protein degrader space. With a discovery engine capable of identifying molecular glue degraders for truly undruggable targets, we note current levels as under-reflecting the breadth of the company's development pipeline."

For an analyst ratings summary and ratings history on Monte Rosa Therapeutics click here. For more ratings news on Monte Rosa Therapeutics click here.

Shares of Monte Rosa Therapeutics closed at $19.29 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)